Renaissance Technologies LLC Has $1.29 Million Stock Position in Myomo, Inc. (NYSEAMERICAN:MYO)

Renaissance Technologies LLC increased its holdings in Myomo, Inc. (NYSEAMERICAN:MYO - Free Report) by 39.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 199,600 shares of the company's stock after acquiring an additional 56,500 shares during the quarter. Renaissance Technologies LLC owned approximately 0.66% of Myomo worth $1,285,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Barclays PLC acquired a new stake in shares of Myomo in the 3rd quarter valued at about $36,000. Jane Street Group LLC acquired a new stake in Myomo during the third quarter valued at approximately $65,000. Russell Investments Group Ltd. bought a new position in Myomo during the 4th quarter worth approximately $229,000. AIGH Capital Management LLC grew its position in shares of Myomo by 21.7% in the 4th quarter. AIGH Capital Management LLC now owns 3,381,567 shares of the company's stock worth $21,777,000 after acquiring an additional 602,719 shares in the last quarter. Finally, Perkins Capital Management Inc. bought a new stake in shares of Myomo in the 4th quarter valued at approximately $483,000. Hedge funds and other institutional investors own 44.99% of the company's stock.

Myomo Stock Performance

Myomo stock traded up $0.17 during mid-day trading on Friday, hitting $4.91. 266,680 shares of the company's stock traded hands, compared to its average volume of 349,243. Myomo, Inc. has a one year low of $2.76 and a one year high of $7.17. The company has a 50 day moving average price of $4.85. The firm has a market cap of $148.44 million, a P/E ratio of -21.35 and a beta of 1.68.

Wall Street Analyst Weigh In

MYO has been the topic of several research analyst reports. Craig Hallum raised their price objective on Myomo from $9.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, March 11th. Ascendiant Capital Markets boosted their price objective on shares of Myomo from $9.00 to $11.00 and gave the company a "buy" rating in a research report on Monday, March 17th. HC Wainwright raised their target price on shares of Myomo from $7.50 to $9.50 and gave the stock a "buy" rating in a report on Wednesday, March 12th. Finally, Alliance Global Partners restated a "buy" rating on shares of Myomo in a research note on Tuesday, March 11th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Myomo currently has a consensus rating of "Buy" and an average price target of $9.75.

Insider Buying and Selling

In other news, insider Micah Mitchell sold 48,000 shares of the business's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $5.16, for a total transaction of $247,680.00. Following the sale, the insider now directly owns 140,572 shares of the company's stock, valued at $725,351.52. The trade was a 25.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas F. Kirk acquired 7,400 shares of the business's stock in a transaction on Thursday, March 13th. The shares were bought at an average price of $5.00 per share, for a total transaction of $37,000.00. Following the acquisition, the director now owns 255,933 shares in the company, valued at approximately $1,279,665. This trade represents a 2.98 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 4.54% of the company's stock.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.